[go: up one dir, main page]

WO1997039326A3 - Dosage in vitro a polarisation de fluorescence - Google Patents

Dosage in vitro a polarisation de fluorescence Download PDF

Info

Publication number
WO1997039326A3
WO1997039326A3 PCT/US1997/006746 US9706746W WO9739326A3 WO 1997039326 A3 WO1997039326 A3 WO 1997039326A3 US 9706746 W US9706746 W US 9706746W WO 9739326 A3 WO9739326 A3 WO 9739326A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
test substance
emission
mixture
pair
Prior art date
Application number
PCT/US1997/006746
Other languages
English (en)
Other versions
WO1997039326A2 (fr
Inventor
Berkley A Lynch
Ian A Macneil
Mark J Zoller
Original Assignee
Ariad Pharma Inc
Berkley A Lynch
Ian A Macneil
Mark J Zoller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc, Berkley A Lynch, Ian A Macneil, Mark J Zoller filed Critical Ariad Pharma Inc
Priority to EP97922393A priority Critical patent/EP0898709A2/fr
Priority to AU28076/97A priority patent/AU727108B2/en
Priority to JP09530451A priority patent/JP2000512737A/ja
Publication of WO1997039326A2 publication Critical patent/WO1997039326A2/fr
Publication of WO1997039326A3 publication Critical patent/WO1997039326A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé de dosage in vitro permettant d'identifier une substance test qui inhibe l'association mutuelle d'une paire de protéines. Ce procédé consiste à produire une paire de protéines aptes à s'associer, l'une des protéins étant porteuse d'une substande fluorescente liée de manière covalente; à préparer un mélange contenant les deux protéins et au moins une substance test; à irradier le mélange avec de la lumière polarisée d'une longueur d'onde appropriée permettant l'excitation de la substance fluorescente telle que l'indique l'émission de lumière polarisée; à mesurer le degré de polarisation de l'émission et à déterminer l'effet dû à la présence ou à la concentration de la substance test en réduisant la polarisation de l'émission observée d'un mélange de deux protéines seules. L'activité inhibitrice de la substance test est en corrélation avec les valeurs réduites de dépolarisation.
PCT/US1997/006746 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence WO1997039326A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP97922393A EP0898709A2 (fr) 1996-04-18 1997-04-18 DOSAGE $i(IN VITRO) A POLARISATION DE FLUORESCENCE
AU28076/97A AU727108B2 (en) 1996-04-18 1997-04-18 In vitro fluorescence polarization assay
JP09530451A JP2000512737A (ja) 1996-04-18 1997-04-18 試験管内蛍光偏光検定法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1559096P 1996-04-18 1996-04-18
US60/015,590 1996-04-18
US2987096P 1996-11-06 1996-11-06
US60/029,870 1996-11-06

Publications (2)

Publication Number Publication Date
WO1997039326A2 WO1997039326A2 (fr) 1997-10-23
WO1997039326A3 true WO1997039326A3 (fr) 1997-12-24

Family

ID=26687596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006746 WO1997039326A2 (fr) 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence

Country Status (5)

Country Link
EP (1) EP0898709A2 (fr)
JP (1) JP2000512737A (fr)
AU (1) AU727108B2 (fr)
CA (1) CA2250067A1 (fr)
WO (1) WO1997039326A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018956A1 (fr) * 1996-10-28 1998-05-07 Panvera Corporation Mesure de l'activite de la kinase par polarisation de fluorescence
US7105307B2 (en) 1997-08-30 2006-09-12 Cyclacel, Ltd. Compositions and methods for screening for modulators of enzymatic activity
CN1157602C (zh) * 1997-09-05 2004-07-14 松下电器产业株式会社 荧光偏振法检测样品的方法及其中使用的试剂
GB9923208D0 (en) * 1999-10-01 1999-12-08 Cambridge Drug Discovery Ltd Assay
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
CN1257408C (zh) * 2001-07-02 2006-05-24 北极医疗诊断有限公司 双光子吸收二吡咯亚甲基二氟化硼染料及其应用
ATE339475T1 (de) 2001-07-02 2006-10-15 Arctic Diagnostics Oy Verfahren zur hydrophilierung von fluoreszierenden markierstoffen
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1656376A1 (fr) 2003-08-22 2006-05-17 Avanir Pharmaceuticals Derives de naphtyridine substitues servant d'inhibiteurs de facteur d'inhibition de la migration des macrophages et leur utilisation pour traiter des maladies humaines
NZ549847A (en) * 2004-03-18 2009-08-28 Transtech Pharma Inc Fluorescence polarization assay
US7608407B2 (en) * 2004-11-16 2009-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay for determining histidine decarboxylase activity
US20060229314A1 (en) 2005-03-24 2006-10-12 Jagadish Sircar Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
WO2013056720A1 (fr) * 2011-10-18 2013-04-25 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Colorants fluorescents comportant des groupes hydroxyméthyle phosphorylés et leur utilisation en microscopie photonique et dans des techniques d'imagerie
EP2944958A1 (fr) 2014-04-04 2015-11-18 Techno-Path (Distribution) Procédé de prédiction d'instabilité phénotypique dans une cellule
WO2016008671A1 (fr) * 2014-07-15 2016-01-21 Valitacell Limited Procédé de mesure de concentration d'anticorps dans un échantillon
EP3075844A1 (fr) 2015-04-01 2016-10-05 Valitacell Limited Procédé de détermination d'une caractéristique fonctionnelle ou de composition d'un milieu de culture cellulaire

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
EP0449269A1 (fr) * 1990-03-27 1991-10-02 Roche Diagnostics GmbH Méthode pour la détection des protéines contenant tyrosine phosphorylée
WO1993003377A1 (fr) * 1991-07-31 1993-02-18 Ziltener Hermann J Procede de detection de restes de phosphotyrosine
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
WO1997010253A1 (fr) * 1995-09-15 1997-03-20 Merck & Co., Inc. Dosage a rendement eleve utilisant des proteines hybrides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
EP0449269A1 (fr) * 1990-03-27 1991-10-02 Roche Diagnostics GmbH Méthode pour la détection des protéines contenant tyrosine phosphorylée
WO1993003377A1 (fr) * 1991-07-31 1993-02-18 Ziltener Hermann J Procede de detection de restes de phosphotyrosine
US5352660A (en) * 1991-10-31 1994-10-04 Mount Sinai Hospital Corporation Method for assaying for a substance that affects a SH2-phosphorylated ligand regulatory system
WO1997010253A1 (fr) * 1995-09-15 1997-03-20 Merck & Co., Inc. Dosage a rendement eleve utilisant des proteines hybrides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. A. LYNCH ET AL: "A fluorescence polarisation based Src-SH2 binding assay.", ANALYTICAL BIOCHEMISTRY., vol. 247, no. 1, 1997, NEW YORK US, pages 77 - 82, XP002045666 *
P. WU ET AL: "A high-throughput STAT binding assay using fluorescence polatization.", ANALYTICAL BIOCHEMISTRY., vol. 249, no. 1, 1997, NEW YORK US, pages 29 - 36, XP002045667 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes

Also Published As

Publication number Publication date
AU727108B2 (en) 2000-11-30
EP0898709A2 (fr) 1999-03-03
WO1997039326A2 (fr) 1997-10-23
AU2807697A (en) 1997-11-07
JP2000512737A (ja) 2000-09-26
CA2250067A1 (fr) 1997-10-23

Similar Documents

Publication Publication Date Title
WO1997039326A3 (fr) Dosage in vitro a polarisation de fluorescence
AU5884394A (en) Method and device for assessing the suitability of biopolymers
ATE317122T1 (de) Fluoreszierende polarisation
ATE386815T1 (de) Methoden und syteme zur überwachung intrazellulärer bindereaktionen
DE69840146D1 (de) Fluoreszenzprotein-sensoren zur erkennung von analyten
WO2006023725A3 (fr) Systeme de detecteur de ph fluorescent et procedes associes
WO2004000884A3 (fr) Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
DE69033067D1 (de) 4,7-dichlorfluoreszein-farbstoffe als molekulare sonden
CA2263888A1 (fr) Procedes et compositions servant a detecter le cancer du col de l'uterus
WO2001040757A3 (fr) Cavites optiques resonnantes destinees a des biodetecteurs a grande sensibilite et a haut rendement et procedes utilisant ces biodetecteurs
AU637017B2 (en) Merocyanine and nitro or nitroso substituted polyhalogenated phenolsulfonephthaleins as protein indicators in biological samples
AR027346A1 (es) Tira de analisis reactiva para la determinacion de analitos
CA2217700A1 (fr) Procede de detection de substances biologiquement actives
ATE449963T1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
CA2330629A1 (fr) Procede et dispositif permettant de prevoir des valeurs de mesures physiologiques
CA2356442A1 (fr) Essai in vitro recourant a la spectroscopie rmn utilisant l'hyperpolarisation
Ci et al. Fluorimetric determination of human serum albumin with eriochrome cyanine R
AU2841695A (en) A method for detecting disturbances of the protein C/protein S system
DE60228196D1 (de) System und verfahren zur in-vitro-analyse von therapeutischen wirkstoffen
WO2000023615A3 (fr) Procede ameliore destine a une extraction quantitative d'information se rapportant a une influence sur une reponse cellulaire
DE60010323D1 (de) Fluoreszenzkorrelationsspektroskopie zur identifizierung von verbindung-ziel-bindung
Miyoshi et al. Investigation of the interaction mode of phenothiazine neuroleptics with α1‐acid glycoprotein
WO2002066982A8 (fr) Analyse de modifications et de demodifications de proteines avec des proteines apparentees a l'ubiquitine par fret (transfert d'energie de resonance par fluorescence)
CA2384170A1 (fr) Sonde de visualisation de gmp cyclique et procede de detection et de quantification de gmp cyclique faisant intervenir cette sonde

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2250067

Country of ref document: CA

Ref country code: CA

Ref document number: 2250067

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997922393

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997922393

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997922393

Country of ref document: EP